CeriBell Cash Flow Statement
NASDAQ: CBLLHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
23.63+0.48 (+2.07%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CeriBell free cash flow
In fiscal 2025, CeriBell generated -$40.8 million of operating cash flow and spent $767,000 on capital expenditures. That left free cash flow of -$41.6 million, a free-cash-flow margin of -46.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
CeriBell cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -53.41M | -40.45M | -29.46M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 1.34M | 1.14M | 847.00K |
| Stock-Based Compensation | 12.22M | 5.41M | 2.68M |
| Change in Working Capital | -2.46M | -4.99M | -5.20M |
| Operating Cash Flow | -40.81M | -35.04M | -29.16M |
| Capital Expenditures | -767.00K | -1.34M | -983.00K |
| Investing Cash Flow | -118.14M | -1.60M | -1.76M |
| Debt Issued | 0 | 7.91M | — |
| Debt Repaid | — | — | -3.75M |
| Financing Cash Flow | 5.05M | 196.52M | -2.82M |
| Net Change in Cash | -153.89M | 159.88M | -33.74M |
| Free Cash Flow | -41.58M | -36.38M | -30.14M |
This table shows 3 annual periods of CeriBell's cash flow statement, from FY 2025 back to FY 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CBLL's reporting calendar. What is a cash flow statement?